Linking epigenetics to tumor heterogeneity, upon exposure to targeted therapies, elevated KDM5B expression shifts melanoma cells to a more drug-tolerant CD34- state while KDM5B loss shifts melanoma cells to a more sensitive CD34+ state. Here, KDM5B is linked to neoplasm.